PortenoyRK, FoleyKM, StulmanJ, . Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations, and the consequences of renal failure. Pain1991; 47: 13–19.
OsborneRJ, JoelSP, TrewDM, . The analgesic activity and pharmacokinetics of morphine-6-glucuronide in man (abstract). Proc ASCO1989; 8 (258):67.
5.
KeikoRF, FoleyKM, GrabinskiPY, . Central nervous system excitatory effects of morphine in cancer patients. Ann Neurol1983; 13 (2):180–185.
6.
SearJW, HandCV, MooreRA, . Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anesth1989; 62: 28–32.
PelligrinoDA, RieglerFX, AlbrechtRF. Ventilatory effects of fourth cerebroventricular infusions of morphine-6 or morphine-3-glucuronide in the awake dog. Anesthes1989; 71: 936–940.
12.
SaweJ, Odar-CederlafI.Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol1987; 32: 377–382.
